US Markets

Snowflake remains one of the highest-quality data + AI infrastructure platforms globally, positioned at the centre of enterprise data workflows.

The investment case is simple:

• Structural tailwind: Explosion in data + AI workloads
• Platform leverage: Usage-based model scales with customer success
• Margin expansion: Strong operating leverage as revenue scales

👉 The market is pricing Snowflake as a ~25–30% revenue compounder with accelerating earnings power

📊 Revenue Growth Profile

Key Drivers

• Enterprise data migration to cloud
• AI / machine learning workloads
• Expansion within existing customers (land → expand model)

👉 Takeaway:
Revenue growth is high but normalising, still well above most large-cap software peers.

Based on current market estimates as of April 30, 2026, Snowflake (SNOW) is expected to report its fiscal first quarter 2027 results in late May.

Estimated Earnings Date

• Primary Estimate: Wednesday, May 27, 2026 (After market close).
• Secondary Estimate: Some analysts project the release could occur as early as Wednesday, May 20, 2026.
• Official Confirmation: Snowflake typically issues a press release confirming the exact date and time in early May (last year, the announcement was made on May 1st).

Q1 FY2027 Analyst Expectations
Analysts are currently forecasting the following metrics for the quarter ending April 30, 2026:

Implied Growth: This would represent approximately 27% year-over-year revenue growth.

Consensus EPS Forecast: ~$0.32 (estimates range from $0.14 to $0.32 depending on the source).

Revenue Forecast: ~$1.32 billion.

{NAS.ISRG} is a dominant leader in the robotic-assisted surgery market, known for its da Vinci surgical systems.

Earnings Alert: Q1 2026

• Release Date: Tomorrow, April 21, 2026, after market close.
• Estimates: Analysts expect EPS of approximately $2.08 – $2.16 on revenue of $2.61 – $2.67 billion.

Key Focus: Investors will be watching for updates on the rollout of the da Vinci 5* and commentary on 2026 procedure growth guidance (currently 13–15%).

Fundamental Metrics

• Market Cap: ~$166.65 Billion.
• Valuation:

* Forward P/E: 41.06x
* Trailing P/E: 59.54x
* Price-to-Book: 9.35x

• Analyst Sentiment: Rated as a Buy (Average Rating: 1.9) with a median price target generally cited near $600, implying significant potential upside from current levels.

Recent Developments & Catalysts
FDA Expansions: In early 2026, the company received FDA clearance for the da Vinci 5for select cardiac procedures and recently expanded da Vinci SP* indications to include inguinal hernia and appendectomy.

• Operational Milestone: The company reached a milestone of 20 million procedures performed globally in January 2026, reinforcing its massive “razor-and-blade” recurring revenue model (instruments and accessories).
• Guidance Caution: The stock has seen some pressure in early 2026 due to conservative procedure growth guidance (13-15% vs. 18% in 2025), as the company laps tough year-over-year comparisons.

Performance Context

• 52-Week Range: $427.84 – $603.88.
• Technical Trend: The stock is currently trading below its 200-day moving average ($503.09), suggesting it is in a period of consolidation or correction ahead of its earnings results. It has underperformed the broader S&P 500 YTD by approximately 18%.

Actionable Insight: ISRG remains a high-quality growth play, but current valuation multiples reflect high expectations. Tomorrow’s earnings call will be critical to determine if the 2026 growth deceleration is fully priced in.

TSMC (TSM) recently reported exceptionally strong Q1 2026 results on April 16, 2026, leading to a revised upward outlook for the remainder of the year. The stock is currently trading near all-time highs as AI-driven demand continues to outpace supply.

Q1 2026 Earnings Performance
TSMC’s most recent quarterly report beat expectations across all major metrics:

• Revenue: $35.9 billion (NT$1,134.1 billion), a 35.1% increase year-over-year.
• EPS: $3.49 per ADR (NT$22.08), exceeding analyst consensus of ~$3.35.
• Profitability: Gross margins reached 66.2% and operating margins hit 58.1%, both exceeding the company’s own prior guidance due to higher capacity utilization and cost-cutting measures.
• Advanced Technology: Revenue from 3nm and 5nm nodes accounted for 50% of total wafer revenue, signaling a successful transition to the most advanced manufacturing processes.

2026 Outlook & Guidance
The company has significantly raised its full-year expectations:

• Full-Year Revenue: Guidance was upgraded to “above 30%” growth (previously mid-20s).
• Q2 2026 Guidance: Revenue is expected between $39.0B and $40.2B, representing continued sequential growth.
• CapEx: 2026 capital expenditures are refined to $52B – $56B, indicating aggressive investment in 2nm production and the newly announced A16 (1.6nm) process technology.

Valuation Metrics

• Trailing P/E: 31.86x
• Forward P/E: 19.35x (indicates strong expected earnings growth in the coming 12 months).
• Dividend Yield: ~0.95% ($3.51/share annually).

Key Investment Considerations

TSMC remains the sole provider for high-end AI chips (NVIDIA, Apple, AMD). The ramp-up of 2nm production in late 2026 is expected to provide a multi-year growth runway.

Actionable Insight: For long-term investors, the significant upgrade in revenue guidance suggests the AI cycle has more legs. However, at $370+, the stock is approaching some analysts’ price targets (e.g., Needham at $480), suggesting new entries might wait for minor pullback.